Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Affimed Therapeutics, a developer of next generation antibody therapeutics, has announced a second closing of E5 million to its series B funding.
Subscribe to our email newsletter
This addition increases the total for the round to E30 million in equity. The capital increase was subscribed by Novo Nordisk via Novo Nordisk Biotech Fund, Novo Nordisk’s internal corporate venture fund.
The money raised in this series B financing will be used to fund Affimed’s proprietary therapeutic antibody programs. Based on its proprietary TandAb tetravalent antibody format the company will focus specifically on the two clinical lead programs, a TandAb for the treatment of Hodgkin’s disease and another for the treatment of Non-Hodgkin’s lymphoma. Affimed also plans to advance additional pre-clinical antibody programs for various other oncology and anti-inflammatory indications.
Rolf Gunther, CEO of Affimed, said: “This additional investment will further leverage the clinical development of our lead antibodies.”